Galmed Pharmaceuticals
GLMD
23 hedge funds and large institutions have $4.47M invested in Galmed Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
94% more call options, than puts
Call options by funds: $31K | Put options by funds: $16K
0.02% less ownership
Funds ownership: 0.09% → 0.06% (-0.02%)
4% less funds holding
Funds holding: 24 → 23 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
37% less capital invested
Capital invested by funds: $7.05M → $4.47M (-$2.58M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$61.2K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$41.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19.8K |
| 4 |
Morgan Stanley
New York
|
+$7.08K |
| 5 |
Citigroup
New York
|
+$1.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$1.59M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$211K |
| 3 |
Millennium Management
New York
|
-$66.9K |
| 4 |
VF
Virtu Financial
New York
|
-$65K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$61.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$65K | -200 | Closed |
|
|
LC
27
Lindbrook Capital
Calabasas,
California
| – | -$21K | -64 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$12K | -35 | Closed |
|
GLMD Hedge Fund Activity: Q1 2022 in Review
23 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2022, worth a combined $4.47M — down 37% from $7.05M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GLMD and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was Raymond James Financial Services Advisors, adding an estimated $61.2K. The largest seller was Ibex Investors, exiting entirely with an estimated $1.59M sold.
- 23 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2022, down from 24 in Q4 2021.
- Funds reported $4.47M of Galmed Pharmaceuticals stock for Q1 2022, down 37% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q1 2022 and 5 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q1 2022 was Raymond James Financial Services Advisors, an estimated $61.2K added.
- The largest Galmed Pharmaceuticals seller in Q1 2022 was Ibex Investors, an estimated $1.59M sold.
Based on aggregated 13F filings for Q1 2022.